Last updated on November 2019

A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered Locally Advanced or Metastatic Triple-Negative Breast Cancer or Hormone Receptor-Positive HER2-Negative Breast Cancer


Find a site near you

Start Over